ACS BrightEdge, the innovation and impact investment arm of the American Cancer Society, focuses on identifying and investing in actionable and scalable solutions that address critical unmet needs in cancer care while generating financial returns to sustain lifesaving work. They operate at the intersection of investment and innovation to define and catalyze scientific, social, and sustainable impact.
| Fund Size | N/A USD |
| Stages Focus | Early-Stage, Seed, Series A |
| Sectors Focus | HealthTech, Biotech, Oncology, Pharmacology, Philanthropy, Fundraising, Drug Discovery, Surgical Devices, Clinics/Outpatient Services |
| Portfolio Size | 2 companies |
ACS BrightEdge's investment thesis is centered on advancing novel therapeutics and technology-enabled solutions designed to improve outcomes and reduce systemic barriers across the cancer care continuum. They aim to generate financial returns while making a significant impact on cancer care.
Active team contains 7 members (2 partners, 0 founders).
ACS BrightEdge is the innovation, impact investment, and venture capital arm of the American Cancer Society, focusing on early-stage companies developing cancer-focused therapeutics, diagnostics, devices, and technologies.
ACS BrightEdge is located in Kennesaw, United States.
This information is not publicly available.
ACS BrightEdge is a Corporate VC and VC Firm.
Yes, ACS BrightEdge invests in HealthTech.
Yes, ACS BrightEdge invests in Biotech.
Yes, ACS BrightEdge invests in Oncology.
Yes, ACS BrightEdge invests in Pharmacology.
Yes, ACS BrightEdge invests in Philanthropy.
Yes, ACS BrightEdge invests in Fundraising.